Objective: To investigate serum insulin growth factor-1 (IGF-1) levels in neurodegenerative disease and to correlate clinical parameters.

Background: IGF-1 is highly expressed in the central nervous systems and participates in brain growth, development, plasticity and neuronal survival. Neuroprotective effects have also been reported by several studies.

Methods: One hundred six patients with neurodegenerative diseases (parkinsonism or dementia disorders) were included in this study. Serum IGF-1 levels were determined and its correlation with clinical factors were assessed. All participants gave their informed consent to participate in this study. For patients with dementia, informed consent from family members was also obtained.

Results: Serum IGF-1 levels were not significantly different among disease, shown as follows: Parkinson’s disease (n=54), 114.9±43.1 ng/ml; progressive supranuclear palsy (n=10), 96.9±22.7 ng/ml; multiple system atrophy (n=18), 104.8±30.8 ng/ml; Alzheimer’s disease (n=14), 95.4±32.1ng/ml; dementia with Lewy bodies (n=6), 81.7±13.5 ng/ml; frontotemporal dementia, (n=4), 80.8±40.1ng/ml. In patients with Parkinson’s disease, serum IGF-1 levels positively correlated with age and the specific binding ratio in the striatum on dopamine transporter (DAT) scan and negatively correlated with Mini-Mental State Examination score. In patients with other parkinsonian disorders, there was no correlation between IGF-1 levels and striatal DAT binding.

Conclusions: There was no significant difference in serum IGF-1 levels in patients with neurodegenerative diseases. The relationship between IGF-1 levels and motor function, quality of life and cognitive functions requires further studies.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/serum-insulin-like-growth-factor-1-levels-in-parkinsonism-or-dementia-disorders/